Clinical Trials Logo
  1. Home
  2. Recurrent Adult Brain Neoplasm
  3. NCT02348255

NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

Recurrent Adult Brain Neoplasm Clinical Trial

Official title:
A Phase II, Multi-institutional Trial of NOVO-TTF-100A, BCNU and Bevacizumab for GBM in First Relapse

Clinical Trial Summary

This phase II trial studies the safety of NovoTTF-100A in combination with bevacizumab and carmustine and to see how well they work in treating patients with glioblastoma multiforme that has returned for the first time. NovoTTF-100A, a type of electric field therapy, delivers low intensity, alternating "wave-like" electric fields that may interfere with multiplication of the glioblastoma multiforme cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving NovoTTF-100A together with bevacizumab and carmustine may be an effective treatment for glioblastoma multiforme.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. Establish the safety of NovoTTF-100A in combination with bevacizumab and BCNU (carmustine) in glioblastoma multiforme (GBM) patients who have relapsed after chemoradiation therapy (first relapse).

II. Determine the 6 month overall survival (OS). III. Determine the 6 month progression free survival (PFS). IV. Evaluate the effect of this therapy regimen on quality-of-life.

OUTLINE:

Patients receive bevacizumab intravenously (IV) over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses. Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.

After completion of study treatment, patients are followed up for 12 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02348255
Study type Interventional
Source University of California, Davis
Contact
Status Withdrawn
Phase Phase 2
Start date January 2016
Completion date January 2017
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00823797 - Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Phase 2
Completed NCT01648348 - Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00329719 - Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma Phase 1/Phase 2
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Completed NCT00979862 - Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma Phase 1
Active, not recruiting NCT02101905 - Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Phase 1
Completed NCT00433381 - Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Phase 2
Terminated NCT01378481 - High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma Phase 1
Completed NCT00049127 - Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Phase 1/Phase 2
Completed NCT01051557 - Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma Phase 1/Phase 2
Completed NCT00423735 - Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Phase 2
Completed NCT00823459 - Everolimus in Treating Patients With Recurrent Low-Grade Glioma Phase 2
Terminated NCT01122888 - Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme Phase 1
Active, not recruiting NCT00268385 - Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas Phase 1
Terminated NCT02967380 - Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases N/A
Active, not recruiting NCT01817751 - Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma Phase 2